皓宸医疗(002622) - 2024 Q4 - 年度业绩预告

Revenue Projections - The estimated revenue for 2024 is projected to be between 800 million and 900 million CNY, compared to 756.71 million CNY in the same period last year, indicating a growth of approximately 5.7% to 18.8%[3] Profit and Loss Expectations - The net profit attributable to shareholders is expected to be a loss of between 40 million and 22 million CNY, an improvement from a loss of 94.37 million CNY in the previous year[3] - The net profit after deducting non-recurring gains and losses is projected to be a loss of between 20 million and 11 million CNY, compared to a loss of 85.10 million CNY last year, showing a significant reduction in losses[3] - The basic earnings per share is expected to be a loss of between 0.0476 CNY and 0.0262 CNY, improving from a loss of 0.1123 CNY per share in the previous year[3] Operational Performance - The company has seen continuous growth in revenue from oral medical services and permanent magnet switch business, contributing to overall operational quality improvement[5] Investment Income and Risk Management - The decline in investment income is attributed to the impairment provisions made by the company's associate, Fushun Bank, to enhance risk resistance capabilities[5] - The company plans to recognize overdue interest based on prudence due to ongoing litigation matters, contributing to the overall expected loss for 2024[5] Financial Reporting - The financial data presented is preliminary and has not been audited, with detailed financial information to be disclosed in the 2024 annual report[7]